Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson’s Disease

Michael Jewett, Elna Dickson, Kajsa Brolin, Matilde Negrini, Itzia Jimenez-Ferrer and Maria Swanberg*

Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden

Parkinson’s disease (PD) is a common, progressive neurodegenerative disease, which typically presents itself with a range of motor symptoms, like resting tremor, bradykinesia, and rigidity, but also non-motor symptoms such as fatigue, constipation, and sleep disturbance. Neuropathologically, PD is characterized by loss of dopaminergic cells in the substantia nigra pars compacta (SNpc) and Lewy bodies, neuronal inclusions containing α-synuclein (α-syn). Mutations and copy number variations of SNCA, the gene encoding α-syn, are linked to familial PD and common SNCA gene variants are associated to idiopathic PD. Large-scale genome-wide association studies have identified risk variants across another 40 loci associated to idiopathic PD. These risk variants do not, however, explain all the genetic contribution to idiopathic PD. The rat Vra1 locus has been linked to neuroprotection after nerve- and brain injury in rats. Vra1 includes the glutathione S-transferase alpha 4 (Gsta4) gene, which encodes a protein involved in clearing lipid peroxidation by-products. The DA.VRA1 congenic rat strain, carrying PVG alleles in Vra1 on a DA strain background, was recently reported to express higher levels of Gsta4 transcripts and to display partial neuroprotection of SNpc dopaminergic neurons in a 6-hydroxydopamine (6-OHDA) induced model for PD. Since α-syn expression increases the risk for PD in a dose-dependent manner, we assessed the neuroprotective effects of Vra1 in an α-syn-induced PD model. Human wild-type α-syn was overexpressed by unilateral injections of the rAAV6-α-syn vector in the SNpc of DA and DA.VRA1 congenic rats. Gsta4 gene expression levels were significantly higher in the striatum and midbrain of DA.VRA1 compared to DA rats at 3 weeks post surgery, in both the ipsilateral and contralateral sides. At 8 weeks post surgery, DA.VRA1 rats suffered significantly lower fiber loss in the striatum and lower loss of dopaminergic neurons in the SNpc compared to DA. Immunofluorescent stainings showed co-expression of Gsta4 with Gfap at 8 weeks suggesting that astrocytic expression of Gsta4 underlies Vra1-mediated neuroprotection to α-syn induced pathology. This is the second PD model in which Vra1 is linked to protection of the nigrostriatal pathway, solidifying Gsta4 as a potential therapeutic target in PD.

Keywords: Parkinson's disease, α-synuclein, dopaminergic neurons, neuroprotection, glutathione S-transferase alpha 4, Vra1
INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) resulting in a range of motor and non-motor symptoms. One of the pathological hallmarks of PD is the accumulation of α-synuclein (α-syn) protein, which is abundant in neuronal inclusions termed Lewy bodies and Lewy neurites (1). About 10% of PD cases are familial, and so far, mutations in seven genes have been linked to PD with a recessive or dominant inheritance pattern (2). The remaining 90% are classified as idiopathic PD with a complex etiology, meaning that both genetic and environmental factors contribute to the disease (3, 4). So far, 41 PD risk loci have been confirmed as associated to idiopathic PD (5, 6). There is, however, still a substantial missing etiology.

The genetics linking α-syn to PD is abundant. Mutations in SNCA encoding α-syn are linked to monogenic PD (22), and copy-number variation of SNCA is linked to PD in a dose-dependent manner with several duplications (23–32) and triplications (32–34) being reported. In addition, common variants of SNCA are associated to idiopathic PD (35). Thus α-syn is clearly implicated in PD etiology and is, therefore, widely used in PD animal models: from transgenic rodent models (36) to viral vector-mediated models (37), with the latter being able to deliver a more consistent and progressive PD-like phenotype (38).

It has been shown that the overexpression of α-syn in rodents through the use of viral vectors leads to a progressive pathology with loss of midbrain dopaminergic neurons (39, 40). In fact, reports have shown that recombinant adeno-associated viral (rAAV) vector-mediated overexpression of α-syn in rats reproduces several of the neuropathological aspects seen in patients (41–43), making it a relevant research model for studying PD. There is also evidence that α-syn activates oxidative stress mechanisms; for example, studies have shown that α-syn overexpression, like 6-OHDA, leads to mitochondrial impairment, which in turn leads to the production of reactive oxygen species (ROS) and lipid peroxidation (44–47).

In this study, we investigated if the Vra1 locus encoding Gsta4 mediates neuroprotection after overexpression of human wildtype (WT) α-syn in the rat SNpc. Compared to DA, DA.VRA1 congenic rats displayed higher gene expression levels of Gsta4 in the striatum and SNpc at 3 weeks after α-syn overexpression. Furthermore, at 8 weeks after α-syn overexpression, we observed less degeneration of dopaminergic fibers in the striatum and their respective cell bodies in the SNpc. Similar to what was previously reported from the 6-OHDA model (21), Gsta4 was expressed in astrocytes in the SNpc at 8 weeks post rAAV injections. These results suggest that the Vra1 locus protects from α-syn-induced PD-like neurodegeneration and that astrocytes mediate this action through expression of Gsta4.

MATERIALS AND METHODS

Research Model

For this study, we used two different inbred strains of rats: Dark Agouti (DA) and DA.VRA1, a congenic strain developed by transferring Vra1 alleles from the PVGav1 strain to a DA background. The congenic DA.VRA1 strain, carrying PVG.1AV1 alleles in the neuroprotective Piebald Virol Glaxo (PVG.1AV1) rat strains (7). The congenic PD etiology.

The genetics linking α-syn to PD is abundant. Mutations in SNCA encoding α-syn are linked to monogenic PD (22), and copy-number variation of SNCA is linked to PD in a dose-dependent manner with several duplications (23–32) and triplications (32–34) being reported. In addition, common variants of SNCA are associated to idiopathic PD (35). Thus α-syn is clearly implicated in PD etiology and is, therefore, widely used in PD animal models: from transgenic rodent models (36) to viral vector-mediated models (37), with the latter being able to deliver a more consistent and progressive PD-like phenotype (38).

It has been shown that the overexpression of α-syn in rodents through the use of viral vectors leads to a progressive pathology with loss of midbrain dopaminergic neurons (39, 40). In fact, reports have shown that recombinant adeno-associated viral (rAAV) vector-mediated overexpression of α-syn in rats reproduces several of the neuropathological aspects seen in patients (41–43), making it a relevant research model for studying PD. There is also evidence that α-syn activates oxidative stress mechanisms; for example, studies have shown that α-syn overexpression, like 6-OHDA, leads to mitochondrial impairment, which in turn leads to the production of reactive oxygen species (ROS) and lipid peroxidation (44–47).

In this study, we investigated if the Vra1 locus encoding Gsta4 mediates neuroprotection after overexpression of human wildtype (WT) α-syn in the rat SNpc. Compared to DA, DA.VRA1 congenic rats displayed higher gene expression levels of Gsta4 in the striatum and SNpc at 3 weeks after α-syn overexpression. Furthermore, at 8 weeks after α-syn overexpression, we observed less degeneration of dopaminergic fibers in the striatum and their respective cell bodies in the SNpc. Similar to what was previously reported from the 6-OHDA model (21), Gsta4 was expressed in astrocytes in the SNpc at 8 weeks post rAAV injections. These results suggest that the Vra1 locus protects from α-syn-induced PD-like neurodegeneration and that astrocytes mediate this action through expression of Gsta4.

The 6-OHDA lesion, however, does not model the α-syn pathology seen in PD.

The genetics linking α-syn to PD is abundant. Mutations in SNCA encoding α-syn are linked to monogenic PD (22), and copy-number variation of SNCA is linked to PD in a dose-dependent manner with several duplications (23–32) and triplications (32–34) being reported. In addition, common variants of SNCA are associated to idiopathic PD (35). Thus α-syn is clearly implicated in PD etiology and is, therefore, widely used in PD animal models: from transgenic rodent models (36) to viral vector-mediated models (37), with the latter being able to deliver a more consistent and progressive PD-like phenotype (38).

It has been shown that the overexpression of α-syn in rodents through the use of viral vectors leads to a progressive pathology with loss of midbrain dopaminergic neurons (39, 40). In fact, reports have shown that recombinant adeno-associated viral (rAAV) vector-mediated overexpression of α-syn in rats reproduces several of the neuropathological aspects seen in patients (41–43), making it a relevant research model for studying PD. There is also evidence that α-syn activates oxidative stress mechanisms; for example, studies have shown that α-syn overexpression, like 6-OHDA, leads to mitochondrial impairment, which in turn leads to the production of reactive oxygen species (ROS) and lipid peroxidation (44–47).

In this study, we investigated if the Vra1 locus encoding Gsta4 mediates neuroprotection after overexpression of human wildtype (WT) α-syn in the rat SNpc. Compared to DA, DA.VRA1 congenic rats displayed higher gene expression levels of Gsta4 in the striatum and SNpc at 3 weeks after α-syn overexpression. Furthermore, at 8 weeks after α-syn overexpression, we observed less degeneration of dopaminergic fibers in the striatum and their respective cell bodies in the SNpc. Similar to what was previously reported from the 6-OHDA model (21), Gsta4 was expressed in astrocytes in the SNpc at 8 weeks post rAAV injections. These results suggest that the Vra1 locus protects from α-syn-induced PD-like neurodegeneration and that astrocytes mediate this action through expression of Gsta4.

MATERIALS AND METHODS

Research Model

For this study, we used two different inbred strains of rats: Dark Agouti (DA) and DA.VRA1, a congenic strain developed by transferring Vra1 alleles from the PVGav1 strain to a DA background strains as previously described (21). 64 male rats were used in this study (33 DA and 31 DA.VRA1 congenics), weighing approximately 220–250 g. Professor Piehl at the Karolinska Institutet, Stockholm, Sweden generously provided the founders for each strain. 51 (28 DA and 23 DA.VRA1) animals were subjected to unilateral injections of an rAAV6 vector construct to overexpress human WT α-syn, while 13 (5 DA and 8 DA.VRA1) rats were injected with the same vector construct to overexpress GFP in the midbrain at 12 weeks of age with the following titers: α-syn (1.2E14gc/ml) and GFP (3.2E14gc/ml). The expression of both transgenes is led by the synapsin-1 promoter and enhanced with the woodchuck hepatitis virus posttranscriptional
regulatory element (WPRE) (42). For quantification of dopaminergic neurodegeneration, the rAAV6-GFP-injected animals of both strains were pooled together as one group and abbreviated DA (GFP). This was done because no differences were found between the two strains after O.D. measurements in the striatum and stereological measurements in the SNpc (see Quantification of Dopaminergic Fiber Loss in the Striatum and Quantification of Dopaminergic Cell Loss in SNpc). The rats were given ad libitum access to food and water during a 12 h light/dark cycle and housed 2–3 per cage. 32 animals were sacrificed at 3 weeks post surgery for gene expression and immunofluorescence analysis, while 32 others were sacrificed at 8 weeks post surgery for histological analysis. All procedures described were approved by the Ethical Committee for the use of laboratory animals in the Lund/Malmö region.

**Surgical Procedure**

All surgical procedures were performed as described previously (21). 3 µl of rAAV6-α-syn or -GFP were unilaterally injected in the SNpc, which was targeting using the following coordinates, given in millimeters relative to bregma and dural surface (48): AP = −5.3, ML = −1.7, DV = −7.2. After the procedure, 0.15 ml Metacam (Apoptekbolaget, Sweden) was injected s.c. for postoperative analgesia. All animals were then placed in clean cages on a heated pad for recovery.

**Tissue Preparation and Histology**

Most tissue preparation and immunostainings were performed as described previously (21) For DAB stainings in this study, the following primary antibodies were used: mouse anti-tyrosine hydroxylase (TH) (1:1,000, Immunostar, Hudson, WI, USA), rabbit anti-vesicular monoamine transporter 2 (VMAT2) (1:4,000, Immunostar Hudson, WI USA), mouse anti-human WT α-syn (1:2,000, Santa Cruz, CA, USA), and chicken anti-GFP (1:20,000 Abcam, Cambridge, UK). The SNpc sections were given an initial antigen-retrieval incubation in Tris/EDTA (pH 9.0) at 80°C for 30 min followed by a minimum of 15 min of error (C.E.) (49) of 0.08 was accepted. The counting criteria used matches the one previously used (21). Three animals were excluded from the analysis due to complications during surgery or with tissue processing, leaving 7 DA, and 6 DA.VRA1 for quantification. Striatum divisions between D and ventral (V) are shown in Figure 2B.

**Quantification of Dopaminergic Cell Loss in SNpc**

Dopaminergic neurons in the SNpc were quantified by stereology of TH+ cells according to the optical fractionator principle using the Stereo Investigator software (MBF Bioscience, USA) as described previously (21). With a Leitz DMRBE microscope (Leica, Germany), a 5x objective was used to delineate the areas of interest for each section, and a 100x oil-immersion objective was used for the cell counting. A frame ratio of 11% was assigned to each slide, and the average mounted section thickness (h) was 24.3 µm (±2.1). The average number of dopaminergic neurons counted in each individual was 286 (±73). A maximal Gundersen coefficient of error (C.E.) (49) of 0.08 was accepted. The counting criteria used matches the one previously used (21). Three animals were excluded from the analysis due to complications during surgery or with tissue processing, leaving 7 DA, and 6 DA.VRA1 for quantification.

**Gene Expression Analysis**

Animals were sedated and sacrificed at 3 weeks postsurgery as described previously (21). Pieces of right and left striatum and ventral midbrain weighing approximately 30 mg were dissected from the brain and placed in lysing matrix beads tubes (MP Biomedicals, USA) and immediately stored at −80°C. The RNaseasy Mini kit (Qiagen, Germany) was used to extract RNA from these samples, following the supplier’s protocol with some variations already mentioned in Jewett et al. (21). Reverse Transcription and Quantitative (RT)-PCR followed using the SuperScript® III First-Strand Synthesis System (Invitrogen, USA) and SsoAdvanced Universal SYBR green Supermix (BioRad, USA), respectively. qPCR was performed with this protocol: 5 µl Supermix + 0.5 µl of each primer + 4 µl cDNA for each sample. Sample amplification followed this 3-step protocol (1,30 s at 95°C; 2.60 s at 62°C for 39 cycles; 3.5 min at 68°C) with the following primers (5′-3′): Gsta4 (fw: GACCGTCTGAGATTCTTAGTGA, rev: TGCCCTCAGAATGCTCTGT), gapdh (fw: CACCTCCC TCAAGATTTGCAACCA, rev: GGCATGGACTGTTGCTCATGA) and β-actin (fw: AAGTCCCTACCTCCCTCCCAAAAG, rev: AAGCAATGCTGTACCTTCCCC). Levels of Gsta4 gene expression were calculated using 2−ΔΔCq (50) and normalized relating
each value to CL DA of within the respective brain regions (striatum and SNpc).

Statistical Analysis
All statistics were performed with GraphPad Prism (version 7, La Jolla, CA, USA). Values are expressed as mean ± SD. Due to the low number of animals used for each data set, a Shapiro-Wilk normality test was performed to determine whether to proceed with parametric or non-parametric tests. Stereology and densitometry differences between groups were analyzed using a one-way ANOVA followed by Bonferroni’s multiple comparisons post hoc test; statistical significance was set at p-value < 0.05. Correlation analysis was performed using the Pearson correlation coefficient (r), statistical significance was set at p-value <0.05, and a 95% confidence interval was used. A one-way ANOVA was used to calculate gene expression differences between groups at each time point, followed by Bonferroni’s multiple comparisons post hoc test.

RESULTS

DA.VRA1 Rats Present Higher Levels of Gsta4 Gene Expression
Glutathione S-transferase alpha 4 has been shown to be upregulated in IL and CL sides of both striatum and midbrain of DA and DA.VRA1 rats at 2 days post striatal 6-OHDA injections, which is when the first signs of neuronal degeneration become evident within that model (20, 21). For this study, we wanted to investigate Gsta4 expression levels within those same regions at a time point relevant to dopaminergic degeneration within the model of nigral rAAV-α-syn overexpression. We, therefore, chose to assess gene expression of Gsta4 at 3 weeks after rAAV-mediated α-syn injections in the SNpc using the CL striatum and midbrain regions as internal controls (42). Gsta4 expression is significantly higher in the striatum (Figure 1A) (p < 0.05) and midbrain (Figure 1B) (p < 0.01) of DA.VRA1 compared to DA rats. There are no differences in Gsta4 expression between the CL and IL side within each strain (Figures 1A,B).

DA.VRA1 Congenic Rats Display Less Dopaminergic Fiber Loss After α-Syn Overexpression
The rAAV-α-syn model was chosen because it has been shown to produce partial and progressive degeneration of dopaminergic fibers in the striatum and cell bodies in the SNpc, a hallmark of PD (42). In order to evaluate accurate targeting and expression of the transgenes, striatum and midbrain sections were stained for GFP and human WT α-syn. The histological analysis shows high levels of both GFP and α-syn expression with accurate targeting of the nigrostriatal pathway (Figure 2A). Furthermore, our stainings of dopaminergic (TH+) fibers in the striatum indicate that mainly the dorsal striatum was denervated upon α-syn overexpression. Therefore, the striatum was subdivided into dorsal, mainly innervated by the SN, and ventral, mainly innervated by the ventral tegmental area (51) (Figure 2B). Optical densitometry measuring the density of TH+ fibers of the IL compared to the CL striatum points to a higher proportion of remaining TH+ fibers in the IL dorsal striatum of DA.VRA1 compared to DA rats [mean (SD): 69 (13) vs. 54 (9)%, p < 0.023], with DA(GFP) animals being unaffected (Figure 2C). PVG.1AV1 alleles in the Vra1 locus thus protected striatal dopaminergic fibers of DA.VRA1 congenic rats from α-syn-induced degeneration.

DA.VRA1 Congenic Rats Are Partially Protected From Dopaminergic Cell Loss in SNpc
Midbrain dopaminergic neurons were quantified at 8 weeks post α-syn overexpression and GFP as a control (Figures 3A–D). Stereological cell counting performed with TH+–stained sections shows a reduction in dopaminergic cells in the IL SNpc of both DA and DA.VRA1 congenic rats compared to DA(GFP); however, there was no significant difference in the proportion of remaining TH+ neurons between DA and DA.VRA1 rats [50 (9) vs. 40 (8)%; p = 0.06, Figure 3B]. Due to the possibility of TH being downregulated, thus giving an underestimation of dopaminergic neurons, VMAT2 was also used as a
dopaminergic marker to stain and count nigral cells. VMAT2 is a molecule essential for recruiting cytosolic dopamine into synaptic vesicles, and is, therefore, considered a reliable marker for dopaminergic cells (52, 53). Indeed, when quantifying VMAT2+ neurons, we can see Vra1-mediated protection of nigral dopaminergic neurons in the IL SNpc of DA.VRA1 congenic vs DA rats [54 (7) vs. 44 (7)%,
\( p < 0.004, \text{Figure 3D} \)].

In order to verify whether the loss of dopaminergic fibers in the striatum reflects the extent of dopaminergic cell death in both strains, we performed a correlation analysis between the two sets of data. We found a strong positive correlation between striatal TH+ fiber density and remaining dopaminergic cells in the SNpc marked with VMAT2 in both strains (\( p < 0.002; r = 0.8, \text{Figure 3E} \)).

**Gsta4 Is Expressed in Midbrain Astrocytes**

We have previously observed Gsta4 expression in astrocytes but not in microglia or neurons at 8 weeks after 6-OHDA lesion (21). We made the same evaluation with double fluorescence immunostainings on midbrain sections combining Gsta4 with astrocytic (Gfap), microglial (Iba1), or neuronal (NeuN) markers at 8 weeks after \( \alpha \)-syn overexpression (Figure 4). The stainings reveal a similar co-localization pattern of Gsta4 with Gfap (Figures 4A,D,G,G’ and not Iba1 (Figures 4B,E,H) or NeuN (Figures 4C,F,I) within this model, thus confirming astrocytic expression of Gsta4. This pattern remains constant in DA(GFP), DA, and DA.VRA1 animals (Figures 4A–I). Once again, the co-localization is more clear in the somas of SNpc astrocytes rather than the projections (Figure 4G’).

Since the gene expression analysis was performed at 3 weeks, and in order to check for any visible differences between Gsta4 gene and protein expression patterns at this time point, we chose to look at Gsta4 localization at 3 weeks as well. Immunofluorescent stainings for Gsta4 and Gfap were compared between midbrain and striatum sections at 3 and 8 weeks post rAAV-\( \alpha \)-syn delivery. The staining intensity for both Gsta4 and Gfap is visibly lower at 3 weeks when compared to 8 weeks (Figures 5A–D'). At 3 weeks, Gsta4-stained cell bodies do not stand out compared to the background and less Gfap-positive cells are visible. In addition, no co-localization of Gsta4 is detectable with Gfap (Figures 5A,B), NeuN, or Iba1 (data not shown). However, at 8 weeks post rAAV-\( \alpha \)-syn delivery, there is clear co-localization of Gsta4 and Gfap in both the midbrain and striatum (Figures 5C,D). This suggests a delayed increase in astrocytic Gsta4 expression in response to \( \alpha \)-syn overexpression.

**DISCUSSION**

In this study, we show that PVG alleles in the Vra1 locus partially protect the nigrostriatal pathway of DA.VRA1 congenic rats
from α-syn-induced neurodegeneration. At 3 weeks after unilateral rAAV-α-syn delivery, Gsta4 expression levels were higher in both the IL and CL striatum and midbrain of DA.VRA1 rats compared to DA. When quantifying dopaminergic neurodegeneration at 8 weeks, the density of striatal dopaminergic fibers in the lesioned side was significantly higher in the congenic rats compared to DA, and similar evidence of Vra1-mediated neuroprotection was observed for midbrain dopaminergic cell bodies by stereological cell counts of TH+ and VMAT2+ neurons. These results are in line with our previous observations where DA.VRA1 rats displayed partial dopaminergic neuroprotection to striatal 6-OHDA lesion (21). However, while the toxin-based model results in dopaminergic loss mediated by the generation of ROS and mitochondrial damage, the current study models...
α-syn-induced pathology, similar to that seen in PD patients. In addition, we show that Gsta4 is expressed in the cytoplasm of midbrain and striatal astrocytes at 8 weeks after α-syn overexpression, suggesting that astrocytes play an important role in protecting nearby neurons and neurites from α-syn-induced toxicity.

Our previous work, detailing the neuroprotective effects of Gsta4 after striatal 6-OHDA injections, puts focus on the oxidative stress aspects of PD. The neurodegenerative process of 6-OHDA is thought to be due to accumulation of ROS (20) and high levels of HNE within the affected cells (18, 54). Furthermore, 6-OHDA models have been shown to reproduce progressive and retrograde degeneration of the nigrostriatal pathway, mirroring some aspects of the same degeneration seen in PD patients with mild to moderate stages of the disease (55, 56). However, the striatal 6-OHDA model does not cover other pathogenic mechanisms of PD, such as the production of toxic α-syn species or impaired protein degradation (57). The functional link between α-syn and PD is very strong, with α-syn-containing Lewy bodies being present in both familial and idiopathic PD, and the SNCA gene being both linked to familial PD and associated to the risk of developing idiopathic PD. The rat rAAV-α-syn model employed here is based on the clear link between α-syn and PD-like pathology and complements the 6-OHDA model, which can be considered a model for toxin-induced PD. The rAAV vector used in the current study includes the WPRE element, which amplifies the expression of the transgene and induces unilateral overexpression of α-syn, progressive dopaminergic neurodegeneration, and motor impairment, which peak at 8 weeks postinjections (42). The rAAV-α-syn model also induces more progressive behavioral impairments compared to the striatal 6-OHDA model, probably due to the buildup of toxic α-syn species leading to deficits in synaptic function (57, 58).

With the striatal 6-OHDA model, aiming to examine causality of the neuroprotection observed in DA.VRA1 rats at 8 weeks, we measured Gsta4 expression at 2 and 7 days post lesion, when the very early signs of neurodegeneration are seen in the striatum (59). In the rAAV-α-syn model, the first signs of dopaminergic dysfunction and cell loss occur at 3 weeks postinjection (42). Therefore, to keep within the same line of thinking for this study, we performed gene expression analysis of Gsta4 at 3 weeks. Gsta4 expression was higher in both striatum and midbrain of DA.VRA1 rats compared to DA rats. The strain difference was
seen in both the lesioned and the intact sides, suggesting that α-syn overexpression does not induce Gsta4 gene expression at this time point. Based on the observation that, along with increased Gfap staining, Gsta4 immunostaining was enhanced at 8 weeks compared to 3 weeks post transgene delivery, there might be a delayed increase in Gsta4 gene expression after the α-syn transgene overexpression is established. Alternatively, a modest and continuous increase in Gsta4 gene expression in the DA.VRA1 congenic strain is sufficient to partially protect midbrain dopaminergic cell projections and somas from degeneration.

There is plenty of evidence suggesting that α-syn overexpression increases oxidative stress levels, which is a key feature of PD. Both in vivo and in vitro models have shown that accumulation of α-syn can lead to mitochondrial dysfunction through the inhibition of Complex 1 (C1), which in turn leads to the production of ROS (60–62). Interestingly, it has also been shown that ROS are a result of depleted glutathione (GSH) in PD brains (63) and low levels of GSH can lead to the decrease of C1 activity (64). Indeed, one important aspect of Gsta4 activity is its ability to catalyze the conjugation of GSH to lipid peroxidation by-products such as HNE (9). Furthermore, a study by Shearn et al. on chronic alcohol consumption in a Gsta4 null mouse showed that Gsta4 works as a mitochondrial detoxifier (65). This strongly suggests that α-syn toxicity is partly mediated by oxidative stress mechanisms, mainly acting through the mitochondria in dopaminergic cells and involving GSH metabolism. The fact that we see a similar neuroprotective phenotype of DA.VRA1 rats in both the α-syn overexpression model and the striatal 6-OHDA model strongly suggests that the Vra1 locus encoding Gsta4 regulates key processes in PD-like dopaminergic neurodegeneration. The human ortholog GSTA4 is thus a promising therapeutic target in PD with a complex etiology.

In rat, Gsta4 proteins have been found to be abundant in astrocytes, the choroid plexus, as well as in endothelial cells and/or astrocytic end feet associated with blood vessels, Purkinje cells, and neurons (66). Therefore, regional differences in the cellular and subcellular distribution of Gsta4 are not unlikely. In our previous work where the Vra1 locus was found to protect from striatal 6-OHDA lesions, we aimed to uncover the localization of Gsta4 within the affected areas of the rat brain. We found Gsta4 co-expression with the astrocytic marker Gfap, but not with the microglial (Iba1) or the neuronal (NeuN) markers at 8 weeks post injection (21). In the current study, we confirm the astrocytic localization of Gsta4 at 8 weeks in both DA and DA.VRA1 strains. In a nerve injury model, expression of Gsta4 has been shown in spinal motor neurons and not astrocytes (10). Of note, we cannot rule out the possibility that dopaminergic neurons express Gsta4 at levels not detected by immunostainings in our studies.

The relationship between α-syn and astrocytes is well studied. α-syn is found mainly in neurons, but can often accumulate in astrocytes as well, usually after spreading from neurons (67–69), possibly through cell-to-cell transfer (70). A recent study by Lindström et al. points out the important role of astrocytes in α-synucleinopathies. They show that in a co-culture system, astrocytes engulf large amounts of α-syn oligomers but are subsequently not able to degrade them completely, which leads to the formation of inclusions. It suggested that this is most likely brought on by a dysfunctional lysosomal system. Astrocytes also showed signs of mitochondrial damage caused by the accumulation of these α-syn oligomers (71). Furthermore, studies have shown that astrocytes can produce ROS under stressful conditions (72), thus leaving surrounding neurons susceptible to damage (73). This is relevant to the results obtained from DA.VRA1 congenic rats by us (21) and others (10), since ROS production is increased by 6-OHDA (20), α-syn overexpression (61), and in nerve injury models (74)—all environments where DA.VRA1 rats have been shown to express higher levels of Gsta4. When adding the fact that astrocytes also have a very high activity and release of GSH, which might be neuroprotective in itself (75), the link between Gsta4 activity and α-syn pathology is strengthened. More work is necessary to uncover the specific mechanisms by which Gsta4 protects from PD-like pathology in rat PD models. For example, a more in-depth analysis of the role of Gsta4 in astrocytic mitochondria might help answer key questions surrounding potential neuroprotective mechanisms.

In conclusion, this is the first report suggesting potential neuroprotective effects of the Vra1 locus and Gsta4 in an α-syn-induced PD model. Moreover, this study emphasizes the importance of utilizing animal models with naturally occurring allelic differences in order to gain a better understanding of neurodegenerative diseases with complex traits, such as PD. Gsta4 has now been implicated as a potential neuroprotective agent in both the 6-OHDA and α-syn overexpression PD models, making
the human ortholog a very attractive candidate for future PD therapeutic research.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the Ethical Committee for the use of laboratory animals in the Lund/Malmö region.

AUTHOR CONTRIBUTIONS

MJ and MS conceived and designed the experiments; MJ, ED, KB, MN, and IJ-F performed the experiments; MJ, KB, and ED analyzed the data; MJ and MS wrote the paper with contribution from coauthors.

FUNDING

This study was accomplished within MultiPark—a Strategic Research Area at Lund University and supported by the following foundations: Crafoordstiftelsen, Kungliga Fysiografiska Sällskapet Nilsson-Ehle fondern, Greta och Johan Kocks Stiftelse, Stiftelsen Lars Hiertas Minne, Magnus Bergvalls Stiftelse, Segerfalk’s stiftelse, Thelma Zoëgas stiftelse, Tore Nilsons Stiftelse, Tesdorpf’s Stiftelse, and Per-Erik och Ulla Schyberg’s stiftelse.

REFERENCES

1. Spillantini MG, Crowther RA, Lakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (1998) 95(11): 6469–73. doi:10.1073/pnas.95.11.6469
2. Lill CM. Genetics of Parkinson’s disease. Mol Cell Probes (2016) 30(6):386–96. doi:10.1016/j.mcp.2016.11.001
3. Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, et al. Isogenic human iPSk Parkinson’s model shows nitrative stress-induced dysfunction in MEF2-PGC1alpha transription. Cell (2013) 155(6):1351–64. doi:10.1016/j.cell.2013.11.009
4. Sveinbjörnsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem (2016) 139(Suppl 1):318–24. doi:10.1111/jncc.13691
5. Nalls MA, Pankratz N, Lill CM, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet (2014) 46(9):989–93. doi:10.1038/ng.3043
6. Chang D, Nalls MA, Hallgrímsdóttir JB, Hunkapiller J, van der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet (2017) 49(10):1511–6. doi:10.1038/ng.3955
7. Lidman O, Swanberg M, Horvath L, Broman KW, Olsson T, Piehl F. Discrete scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Proc Natl Acad Sci U S A (1996) 93(7):2896–701. doi:10.1073/pnas.93.7.2896
8. Selley ML. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease. Free Radic Biol Med (1998) 25(2):169–74. doi:10.1016/S0891-5849(98)00021-5
9. Castellani RJ, Perry G, Giedlak SL, Nunomura A, Zhang J, et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett (2002) 319(1):25–8. doi:10.1016/S0304-3900(01)05214-9
10. Glinka Y, Gassen M, Youdim MB. Mechanism of 6-hydroxyp Parkinson’s disease. J Neurotransm Suppl (1997) 50:55–66. doi:10.1007/978-3-7091-6842-4_7
11. Jewett M, Jimenez-Ferrer I, Swanberg M. Astrocytic expression of GSTA4 is associated with dopaminergic neuroprotection in a rat 6-OHDA model of Parkinson’s disease. Brain Sci (2017) 7(7):E73. doi:10.3390/biosci7070073
12. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med (2012) 2(1):a008888. doi:10.1101/cshperspect.a008888
13. Chartier-Harlin MC, Karchgers J, Roumier C, Mouroux V, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet (2004) 364(9440):1167–9. doi:10.1016/s0140-6736(04)17103-1
14. Ibanez B, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet (2004) 364(9440):1167–9. doi:10.1016/s0140-6736(04)17104-3
15. Nishioh K, Hayashi S, Farrow MJ, Singleton AR, Yoshino H, Imai H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol (2006) 59(2):298–309. doi:10.1002/ana.20753
16. Fuchs J, Nilsson C, Karchgers J, Munz M, Larsson EM, Schule B, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 68(12):916–22. doi:10.1212/01.wnl.0000254438.17630.c5
17. Ahn TB, Kim SY, Kim KY, Park SS, Lee DS, Min HJ, et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology (2008) 70(1):43–9. doi:10.1212/01.wnl.0000271080.53272.c7
18. Bruegmann N, Odn P, Gruenewald A, Tadic V, Hagenah J, Seidel G, et al. Re: alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology (2008) 71(16):1294; author reply 1294. doi:10.1212/01.wnl.0000338439.00992.c7
19. Ikeuchi T, Kakita A, Shiga K, Kasugah A, Kaneko H, Tan CF, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol (2008) 65(4):514–9. doi:10.1001/archneur.65.4.514
30. Troiano AR, Cazeneuve C, Le Ber I, Bonnet AM, Lesage S, Brice A. Re: alpha-synuclein gene duplication is present in sporadic Parkinson's disease. Neurology (2008) 71(16):1295–9. doi:10.1212/01.wnl.0000338435.78120.ff

31. Uchiyama T, Ikemoto T, Ouchi Y, Sakamoto M, Kusaka K, Shiga A, et al. Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. Neurology (2008) 71(16):1289–91. doi:10.1212/01.wnl.0000337267.28928.e6

32. Ibanez P, Lesage S, Janin S, Lohmann E, Duril F, Destee A, et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol (2009) 66(1):102–8. doi:10.1001/archneurol.2008.355

33. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science (2003) 302(5646):841. doi:10.1126/science.1090278

34. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 55(2):174–9. doi:10.1002/ana.10846

35. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 41(12):1308–12. doi:10.1038/ng.487

36. Harvey BK, Wang Y, Hoffer BJ. Transgenic rodent models of Parkinson's disease. Neurotoxicology (2001) 22(7):2780–91. doi:10.1016/S0093-9349(02)00124-1

37. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol (1999) 156(1):138–48. doi:10.1006/exnr.1998.7008

38. Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, et al. Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neurosci (2014) 8:155. doi:10.3389/fnana.2014.00155

39. Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol (1998) 152(2):259–77. doi:10.1006/exnr.1998.6848

40. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 175(2):303–17. doi:10.1006/exnr.2002.7891

41. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Jewett et al. VRA1 Protects Dopaminergic Neurons

42. Harvey BK, Wang Y, Hoffer BJ. Transgenic rodent models of Parkinson's disease. Neurotoxicology (2001) 22(7):2780–91. doi:10.1016/S0093-9349(02)00124-1

43. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol (1999) 156(1):138–48. doi:10.1006/exnr.1998.7008

44. Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, et al. Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neurosci (2014) 8:155. doi:10.3389/fnana.2014.00155

45. Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol (1998) 152(2):259–77. doi:10.1006/exnr.1998.6848

46. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 175(2):303–17. doi:10.1006/exnr.2002.7891
72. Sheng WS, Hu S, Feng A, Rock RB. Reactive oxygen species from human astrocytes induced functional impairment and oxidative damage. *Neurochem Res* (2013) 38(10):2148–59. doi:10.1007/s11064-013-1123-z

73. Sugiyama K, Brunori A, Mayer ML. Glial uptake of excitatory amino acids influences neuronal survival in cultures of mouse hippocampus. *Neuroscience* (1989) 32(3):779–91. doi:10.1016/0306-4522(89)90298-4

74. Lieven CJ, Hoegger MJ, Schlieve CR, Levin LA. Retinal ganglion cell axotomy induces an increase in intracellular superoxide anion. *Invest Ophthalmol Vis Sci* (2006) 47(4):1477–85. doi:10.1167/iovs.05-0921

75. Heales SJ, Lam AA, Duncan AJ, Land JM. Neurodegeneration or neuroprotection: the pivotal role of astrocytes. *Neurochem Res* (2004) 29(3):513–9. doi:10.1023/B:NERE.0000014822.69384.0f

**Conflict of Interest Statement:** The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Copyright © 2018 Jewett, Dickson, Brolin, Negrini, Jimenez-Ferrer and Swanberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.